Suresh Pattathil, MD & GM of Allergan AbbVie recently shared insights about Allergan AbbVie. He expressed the operational and cultural integration of Allergan into AbbVie. Despite ongoing challenges in a virtual global environment during the pandemic, the merged entity continues to emphasize its commitment to excellence. They plan on focusing on eyecare, neurosciences, and aesthetics in India.
Operational And Cultural Integration
Pattathil highlighted the ongoing process of merging operations, market access models, and cultural integration. He acknowledged that aspects like mechanism and market access are still a work in progress. The Allergan entity, with its established presence in India spanning 25 years, sets the stage for a promising future. This established presence is coupled with the joint venture with Piramal for local manufacturing of Eye Care products.
Patient Education and Treatment Resumption
Addressing the impact of the pandemic on patient care, Pattathil discussed the importance of continuous patient education and awareness. He credited these efforts for the steady resumption of treatments and surgeries in eye care. The commitment to patient well-being remains a cornerstone of Allergan AbbVie’s approach to navigating challenges posed by the global health crisis.
Product Launch Pipeline and Regulatory Landscape
When questioned about expected approvals and the product launch pipeline, Pattathil acknowledged the ongoing nature of this process. Highlighting the current regulatory framework, which requires a minimum of 24 months from inception to commercial launch, Pattathil hinted at introducing new products in 2022 and 2023, augmenting the existing portfolio, although specific details were not disclosed.
Focus on India
Throughout the interview, the emphasis on India’s strategic importance for Allergan AbbVie was evident. The joint venture with Piramal, coupled with the extensive groundwork laid over the last 25 years, positions the company for a bright future in the Indian market.
Conclusion
In conclusion, Suresh Pattathil’s insights provide a glimpse into Allergan AbbVie’s focused approach in India amid global challenges. The commitment to eye care, neurosciences, and aesthetics, coupled with ongoing efforts in operational integration and patient care, underlines the company’s resilience and determination to navigate the complexities of the healthcare landscape.
As regulatory processes unfold and new products are poised for launch, Allergan AbbVie remains at the forefront of healthcare innovation, shaping its trajectory in the dynamic Indian market.
Courtesy Link (Rehash): https://www.expresspharma.in/allergan-abbvie-in-india-to-continue-high-focus-on-eyecare-neurosciences-and-aesthetics/